Advanced in Peripheral T-Cell Lymphoma

Yao J. Liu

274 Zhijiang Road, 
Shanghai, CN 
Advanced in Peripheral T-Cell Lymphoma
274 Zhijiang Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Yao Liu practices in Shanghai, China. Mr. Liu is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Lichen Simplex Chronicus, Leukoplakia, Liver Cancer, Bone Marrow Transplant, and Splenectomy.

His clinical research consists of co-authoring 718 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Peripheral T-Cell Lymphoma.

Gender
Male

Locations

274 Zhijiang Road, Shanghai, 200071, China
Other Locations
No.19 Jinhua South Road, Xi'an, 710048, China
No.181 HanYu Road, Chongqing, 400030, China
800 Dongchuan Road, Shanghai, 200240, China
China Japan Union Hospital of Jilin University
Changchun, 130033, China
12 Wulumuqi Middle Road, Shanghai, 200040, China
117 Nanjing North Street, Shenyang, 110002, China
No. 83 Wenhua Road, Shenyang, 110840, China
No.92 Zhongnan Street, Suzhou Industiral Park, Suzhou, China
Union Hospital, Wuhan, 430022, China
No.83 Wenhua Road, Shenyang, 110840, China
783 Xindu Avenue, Chengdu, 610500, China
No. 1095, Jiefang Road, Wuhan, 430030, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 2

718 Total Publications

Clinical Potential of Copy Number Aberration as a Diagnostic and Prognostic Biomarker in Lymphoma.
Clinical Potential of Copy Number Aberration as a Diagnostic and Prognostic Biomarker in Lymphoma.
Journal: Technology in cancer research & treatment
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Liu's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 129 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile